DHGAlternative Names: depolymerised holothuria glycosaminoglycan
Latest Information Update: 13 Aug 2002
At a glance
- Originator Taiho Pharmaceutical
- Class Anticoagulants
- Mechanism of Action Glycosaminoglycan stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Deep vein thrombosis; Disseminated intravascular coagulation